Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeut… Read more
Great Novel Therapeutics Biotech & Medicals (7427) - Net Assets
Latest net assets as of June 2025: NT$563.86 Million TWD
Based on the latest financial reports, Great Novel Therapeutics Biotech & Medicals (7427) has net assets worth NT$563.86 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$587.17 Million) and total liabilities (NT$23.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$563.86 Million |
| % of Total Assets | 96.03% |
| Annual Growth Rate | 56.68% |
| 5-Year Change | 425.37% |
| 10-Year Change | N/A |
| Growth Volatility | 28.88 |
Great Novel Therapeutics Biotech & Medicals - Net Assets Trend (2019–2024)
This chart illustrates how Great Novel Therapeutics Biotech & Medicals's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Great Novel Therapeutics Biotech & Medicals (2019–2024)
The table below shows the annual net assets of Great Novel Therapeutics Biotech & Medicals from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$633.32 Million | +2.47% |
| 2023-12-31 | NT$618.04 Million | +71.30% |
| 2022-12-31 | NT$360.80 Million | +73.17% |
| 2021-12-31 | NT$208.35 Million | +72.84% |
| 2020-12-31 | NT$120.55 Million | +79.91% |
| 2019-12-31 | NT$67.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Great Novel Therapeutics Biotech & Medicals's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 37296400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$436.44 Million | 68.91% |
| Other Comprehensive Income | NT$18.36 Million | 2.90% |
| Other Components | NT$723.70 Million | 114.27% |
| Total Equity | NT$633.32 Million | 100.00% |
Great Novel Therapeutics Biotech & Medicals Competitors by Market Cap
The table below lists competitors of Great Novel Therapeutics Biotech & Medicals ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BICECORP S.A
SN:BICECORP
|
$34.02 Million |
|
Rich Sparkle Holdings Limited Ordinary Shares
NASDAQ:ANPA
|
$34.03 Million |
|
Gogoro Inc
NASDAQ:GGR
|
$34.05 Million |
|
Schloss Wachenheim AG
F:SWA
|
$34.06 Million |
|
Sensys Gatso Group AB
ST:SGG
|
$34.00 Million |
|
Critica Ltd
AU:CRI
|
$34.00 Million |
|
Metacon AB
ST:META
|
$33.99 Million |
|
Career Design Center Co. Ltd.
PINK:CAEEF
|
$33.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Great Novel Therapeutics Biotech & Medicals's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 618,036,000 to 633,323,000, a change of 15,287,000 (2.5%).
- Net loss of 104,924,000 reduced equity.
- New share issuances of 188,839,000 increased equity.
- Other comprehensive income increased equity by 18,363,000.
- Other factors decreased equity by 86,991,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-104.92 Million | -16.57% |
| Share Issuances | NT$188.84 Million | +29.82% |
| Other Comprehensive Income | NT$18.36 Million | +2.9% |
| Other Changes | NT$-86.99 Million | -13.74% |
| Total Change | NT$- | 2.47% |
Book Value vs Market Value Analysis
This analysis compares Great Novel Therapeutics Biotech & Medicals's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.35x to 2.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$4.94 | NT$31.40 | x |
| 2020-12-31 | NT$7.61 | NT$31.40 | x |
| 2021-12-31 | NT$9.88 | NT$31.40 | x |
| 2022-12-31 | NT$14.94 | NT$31.40 | x |
| 2023-12-31 | NT$17.03 | NT$31.40 | x |
| 2024-12-31 | NT$15.36 | NT$31.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Great Novel Therapeutics Biotech & Medicals utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6226.94%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-16.57%) is above the historical average (-21.62%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -44.59% | 0.00% | 0.00x | 1.28x | NT$-36.58 Million |
| 2020 | -25.94% | 0.00% | 0.00x | 1.04x | NT$-43.32 Million |
| 2021 | -17.21% | -5691.59% | 0.00x | 1.10x | NT$-56.69 Million |
| 2022 | -15.46% | -10329.44% | 0.00x | 1.03x | NT$-91.86 Million |
| 2023 | -9.96% | -1268.87% | 0.01x | 1.04x | NT$-123.34 Million |
| 2024 | -16.57% | -6226.94% | 0.00x | 1.05x | NT$-168.26 Million |
Industry Comparison
This section compares Great Novel Therapeutics Biotech & Medicals's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,107,525,400
- Average return on equity (ROE) among peers: 2.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Great Novel Therapeutics Biotech & Medicals (7427) | NT$563.86 Million | -44.59% | 0.04x | $34.01 Million |
| Synbio Tech Inc. (1295) | $942.97 Million | 12.01% | 1.00x | $21.72K |
| Apex Biotechnology Corp (1733) | $842.42 Million | 19.18% | 0.14x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $129.07 Million |
| Panion & BF Biotech Inc (1760) | $278.86 Million | -14.55% | 2.31x | $123.88 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.02 Billion | 5.81% | 0.71x | $42.95 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $45.13 Million |
| Level Biotechnology (3118) | $498.78 Million | 7.80% | 0.36x | $22.63 Million |
| GenMont Biotech Inc (3164) | $861.62 Million | 3.30% | 0.66x | $31.27 Million |
| Medigen Biotechnology (3176) | $3.18 Billion | -14.68% | 0.53x | $100.57 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $56.40 Million |